Search research articles
Contact Us
Filters
Showing results (101-110 of 123) with videos related to
Page
of 13
Sort By:
JAMA Oncology
|
October 27, 2022
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
Olivier J van Not, Rik J Verheijden, Alfonsus J M van den Eertwegh, et al.
Pigment Cell & Melanoma Research
|
August 9, 2023
Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort
J S W Borgers, F H Burgers, A Schina, et al.
International Journal of Cancer
|
June 20, 2020
Real-world outcomes of advanced melanoma patients not represented in phase III trials
Michiel C T van Zeijl, Rawa K Ismail, Liesbeth C de Wreede, et al.
British Journal of Cancer
|
April 28, 2025
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy
E J van Dijk, H H Nienhuis, A J M van den Eertwegh, et al.
International Journal of Cancer
|
October 4, 2021
The unfavorable effects of COVID-19 on Dutch advanced melanoma care
Olivier J van Not, Jesper van Breeschoten, Alfonsus J M van den Eertwegh, et al.
Journal of the National Cancer Institute
|
February 21, 2025
Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
Mark Schuiveling, Laurens S Ter Maat, Isabella A J Van Duin, et al.
Journal of Geriatric Oncology
|
May 22, 2021
Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry
Anouk Jochems, Esther Bastiaannet, Maureen J B Aarts, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 5, 2024
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry
A Özkan, E Kapiteijn, F van den Bos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2024
Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056]
A Özkan, E Kapiteijn, F van den Bos, et al.
Annals of Surgical Oncology
|
October 6, 2022
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Stephanie A Blankenstein, Johannes J Bonenkamp, Maureen J B Aarts, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 123) with videos related to
Sort By:
Page
of 13
JAMA Oncology
|
October 27, 2022
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
Olivier J van Not, Rik J Verheijden, Alfonsus J M van den Eertwegh, et al.
Pigment Cell & Melanoma Research
|
August 9, 2023
Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort
J S W Borgers, F H Burgers, A Schina, et al.
International Journal of Cancer
|
June 20, 2020
Real-world outcomes of advanced melanoma patients not represented in phase III trials
Michiel C T van Zeijl, Rawa K Ismail, Liesbeth C de Wreede, et al.
British Journal of Cancer
|
April 28, 2025
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy
E J van Dijk, H H Nienhuis, A J M van den Eertwegh, et al.
International Journal of Cancer
|
October 4, 2021
The unfavorable effects of COVID-19 on Dutch advanced melanoma care
Olivier J van Not, Jesper van Breeschoten, Alfonsus J M van den Eertwegh, et al.
Journal of the National Cancer Institute
|
February 21, 2025
Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
Mark Schuiveling, Laurens S Ter Maat, Isabella A J Van Duin, et al.
Journal of Geriatric Oncology
|
May 22, 2021
Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry
Anouk Jochems, Esther Bastiaannet, Maureen J B Aarts, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 5, 2024
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry
A Özkan, E Kapiteijn, F van den Bos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2024
Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056]
A Özkan, E Kapiteijn, F van den Bos, et al.
Annals of Surgical Oncology
|
October 6, 2022
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Stephanie A Blankenstein, Johannes J Bonenkamp, Maureen J B Aarts, et al.
Page
of 13